Licensing Revenue was Kazia Therapeutics’s largest revenue line in fiscal 2024, bringing in $2.30M of $2.31M (100%).
| Timing of transfer of goods or services [axis] | FY 2024 |
|---|---|
| Licensing Revenue | $2.30M |
| Sale Of Paxalisib | $7.00K |
| Total | $2.31M |
Kazia Therapeutics brought in $2.31M from its two revenue lines in fiscal 2024, the year ended June 30, 2024. Licensing Revenue was the largest at $2.30M (99.7%), ahead of Sale Of Paxalisib at $7.00K (0.3%).
Kazia Therapeutics (KZIA) reports its revenue by timing of transfer of goods or services [axis]. In fiscal 2024, Licensing Revenue was its largest revenue line, bringing in $2.30M (99.7% of the total), followed by Sale Of Paxalisib at $7.00K (0.3%).
Licensing Revenue was Kazia Therapeutics' largest revenue line in fiscal 2024, bringing in $2.30M, or 99.7% of the $2.31M total across its two revenue lines.
Every figure comes from Kazia Therapeutics' annual financial filings, as reported. Each line keeps the name Kazia Therapeutics gives it, and years follow its fiscal calendar.
Kazia Therapeutics' revenue by timing of transfer of goods or services [axis] goes back to fiscal 2024, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.